SCHEMBL1937633

SCHEMBL1937633

CCC(=O)N(C)c1cccc(N)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.43
CYP3A4 P08684 2/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
PPIB P23284 1/20 0.40
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
CLK1 P49759 1/20 0.37
PBRM1 Q86U86 1/20 0.37
DDX3X O00571 1/20 0.37
CASP1 P29466 1/20 0.37
RECQL P46063 1/20 0.37
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4488744 0.85 SIGMAR1 (0.43) SIGMAR1CYP3A4TP53SMN1; SMN2PPIB
SCHEMBL13074834 0.82 GRM5 (0.44) SIGMAR1SMN1; SMN2PPIBALDH1A1KDM4E
SCHEMBL24011585 0.81 HSD17B1 (0.53) SIGMAR1TP53SMN1; SMN2ALDH1A1KDM4E
SCHEMBL31425823 0.81 HSD17B1 (0.53) SIGMAR1TP53SMN1; SMN2ALDH1A1KDM4E
SCHEMBL2020210 0.80 SIGMAR1 (0.47) SIGMAR1CYP3A4SMN1; SMN2ALDH1A1CLK1
SCHEMBL15640887 0.80 SIGMAR1 (0.47) SIGMAR1CYP3A4ALDH1A1CLK1PBRM1
SCHEMBL8884787 0.80 SIGMAR1 (0.50) SIGMAR1CYP3A4ALDH1A1CLK1PBRM1
SCHEMBL4493116 0.80 TP53 (0.43) SIGMAR1CYP3A4TP53SMN1; SMN2ALDH1A1
SCHEMBL737988 0.78 ALDH1A1 (0.47) CYP3A4TP53PPIBALDH1A1KDM4E
SCHEMBL5818752 0.78 KMT2A (0.44) TP53SMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017066428-A1 BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2017-04-20 WO disclosed
US-20110230478-A1 4-Alkyl-substituted diaminopyrimidines Bayer ScienceCrop AG (DE) 2011-09-22 US disclosed
EP-2330904-A2 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES Bayer CropScience AG (DE) 2011-06-15 EP disclosed
WO-2010025863-A2 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES BAYER CROPSCIENCE AG (DE) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230478-A1 4-Alkyl-substituted diaminopyrimidines DPM1, DPYD, POLR1C SIGMAR1 3861/4885CYP3A4 556/4885TP53 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.